Paper Details

  1. Home
  2. Paper Details

Effects of magnetic nanoparticle of fe(3)o(4) and 5-bromotetrandrine on apoptosis of K562/A02 leukemic cells induced by daunorubicin.

Author: ChenBao-An, ChenWen-Ji, ChengJian, DingJia-Hua, GaoChong, GaoFeng, LiGuo-Hong, LiXiao-Mao, LiuLi-Jie, ShenMing-Fang, SunXin-Chen, WangXue-Mei, XuWen-Lin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the potential benefits of combination therapy with magnetic nanoparticles of Fe(3)O(4) and 5-Bromotetrandrine (5-BrTet) for chronic leukemia. Apoptosis was assessed using flow cytometry (FCM), Wright staining, and light microscopy, while BAX and BCL-2 expression levels were measured by Western blot. The combination of daunorubicin (DNR) with either MNP (Fe(3)O(4)) or 5-BrTet showed potent cytotoxic effects on K562/A02 cells. Moreover, co-treatment with MNP (Fe(3)O(4)) and 5-BrTet synergistically enhanced DNR-induced apoptosis in K562/A02 cells, leading to typical apoptotic morphological features. BCL-2 expression was significantly reduced, and BAX expression was markedly increased. The study concluded that MNP (Fe(3)O(4)) or 5-BrTet with DNR can induce apoptosis in K562/A02 cells, demonstrating a synergistic effect when used together. The down-regulation of BCL-2 and up-regulation of BAX may play crucial roles in this effect.
Paper Details　
Original Abstract of the Article :
The aim of this study was to investigate the potential benefit of combination therapy with magnetic nanoparticle of Fe(3)O(4) and 5-Bromotetrandrine (5-BrTet) on chronic leukemia. The apoptosis was detected by flow cytometry (FCM), Wright staining and light microscope; the expressions of BAX and BCL...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/19236747

データ提供：米国国立医学図書館（NLM）

Combating Leukemia: A Multi-pronged Approach in the Desert of Disease

The field of [hematology] is constantly seeking new weapons in the fight against leukemia, a challenging disease that can be likened to a vast and unforgiving desert of uncontrolled cell growth. This study explores the potential of combining daunorubicin, a chemotherapy drug, with either magnetic nanoparticles (MNP) of Fe(3)O(4) or 5-bromotetrandrine (5-BrTet) to enhance the effectiveness of treatment. The researchers, driven by the desire to find more potent and targeted therapies, set out to explore the potential synergistic effects of these combinations, hoping to find a more effective way to combat leukemia cells.

A Multi-pronged Approach: A Collaborative Expedition Through the Desert

The researchers discovered that combining daunorubicin with either MNP or 5-BrTet exhibited a synergistic effect in inducing apoptosis in K562/A02 leukemia cells, suggesting a potential for improved treatment outcomes. This finding is like finding a hidden oasis in the desert, offering a source of refreshment and rejuvenation for those battling this challenging condition.

Navigating the Desert of Leukemia: A Collaborative Approach

This research highlights the potential benefits of combining different therapies to combat leukemia, suggesting a more powerful and targeted approach to treatment. This is like a caravan of travelers working together to overcome the challenges of a desert journey, ensuring a safer and more successful expedition through the desert of disease.

Dr.Camel's Conclusion

The battle against leukemia is a relentless journey through a vast and unforgiving desert of disease. This study suggests that combining daunorubicin with either MNP or 5-BrTet might offer a more potent and targeted approach to treatment, potentially leading to a more successful expedition through the desert of leukemia.

Date :
  1. Date Completed 2011-08-23
  2. Date Revised 2016-10-18
Further Info :

Pubmed ID

19236747

DOI: Digital Object Identifier

1009-2137(2009)01-0054-06

Related Literature

Article Analysis
・Effects of daunorubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.